Clinical usefulness of serum HER2 in gastric cancer (Serum Her2/neu elevation in gastric cancer; A Multicenter trial in Hokkaido)

Clinical usefulness of serum HER2 in gastric cancer (Serum Her2/neu elevation in gastric cancer; A Multicenter trial in Hokkaido) - SHERLOCK 1 Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000009773

Enrollment

300

Registered

2013-01-13

Start date

2011-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Equal to or over 20 years. 2)Histologically confirmed adenocarcinoma of the stomach. 3)Written informed concent can be obtained.

Exclusion criteria

Exclusion criteria: 1)Other malignancies within the last 2 years, except for carcinoma in situ or basal cell carcinoma. 2)Patients who are considered to be ineligible by referring physician.

Design outcomes

Primary

Measure	Time frame
Correlation between tissue HER2 status and serum HER2 level	—

Secondary

Measure	Time frame
The role of human matrix metalloprotease (MMP) and the ADAM family of zinc-dependent metalloproteases for the ectodomain shedding of HER2 ECD in gastric cancer Association between genetic biomarkers and HER2 status in gastric cancer.	—

Countries

Japan

Contacts

Public ContactMayuko Saito

Sapporo Medical University First Department of Internal Medicine

m.saitou@sapmed.ac.jp+81-11-611-2111

Outcome results